Om3gafort^SCC EPA Premium – Spain

Daily dietary supplement containing HIGH CONCENTRATION omega-3:

Om3gafort^SCC uses HIGH CONCENTRATION Omega-3 polyunsaturated fatty acids EPA/DHA, EFFICACY, PURITY and SAFETY obtained with an ENVIRONMENTALLY FRIENDLY technology known as Supercritical Concentration (SCC).

Om3gafort^SCC EPA^SCC uses LiqFillCaps^TM hard capsules that facilitate better absorption of EPA in the body.

LiqFillCaps^TM are an innovative technological concept that provide effective solutions for many of the challenges faced by the pharmaceutical and neutraceutical industry. In particular those related to the low solubility of bioactive ingredients and agents, thus obtaining increased oral bioavailability and absorption.

SUPPLEMENT FACTS

NUTRITION FACTS

Daily dose: 2 capsules. % DV based on daily dose.

*Recommended daily amount as per Directive 2008/100/CE of 28 October 2008.
**Daily value not established.
#Guaranteed minimum quantity of the active ingredient expressed in mg. Percentages calculated on the basis of the minimum quantity expressed in mg are subject to variation.

INGREDIENTS:

Fish Oil: (minimum 65% EPA, minimum 10% DHA), Gelatin, Emulsifier: Soya Lecithin, Antioxidants: natural mixed tocopherols, Color Additives (E124).

Greater concentration, greater efficacy

Cardiovascular protection:

1. Yokoyama M, Origasa H, Matsuzaki M, Matsuzawa Y, Saito Y, Ishikawa Y, Oikawa S, Sasaki J, Hishida H, Itakura H, Kita T, Kitabatake A, Nakaya N, Sakata T, Shimada K, Shirato K; Japan EPA lipid intervention study (JELIS) Investigators. Effects of eicosapentaenoic acid on major coronary events in hypercholesterolaemic patients (JELIS): a randomised open-label, blinded endpoint analysis. Lancet. 2007 Mar 31;369(9567):1090-8.
2. Marik PE, Varon J. Omega-3 dietary supplements and the risk of cardiovascular events: a systematic review. Clin Cardiol. 2009 Jul;32(7):365-72.
3. Rupp H. Omacor (prescription omega-3-acid ethyl esters 90): From severe rhythm disorders to hypertriglyceridemia. Adv Ther. 2009 Jul;26(7):675-90. Epub 2009 Jul 27.
4. Anand RG, Alkadri M, Lavie CJ, Milani RV. The role of fish oil in arrhythmia prevention. J Cardiopulm Rehabil Prev. 2008 Mar-Apr;28(2):92-8.
5. Adkins Y, Kelley DS. Mechanisms underlying the cardioprotective effects of omega-3 polyunsaturated fatty acids. J Nutr Biochem. 2010 Apr 9.
6. Chan EJ, Cho L. What can we expect from omega-3 fatty acids? Cleve Clin J Med. 2009 Apr;76(4):245-51.

High blood pressure (Hypertension):

1. Miyajima T, Tsujino T, Saito K, Yokoyama M. Effects of eicosapentaenoic acid on blood pressure, cell membrane fatty acids, and intracellular sodium concentration in essential hypertension. Hypertens Res. 2001 Sep;24(5):537-42.
2. Breslow JL. n-3 fatty acids and cardiovascular disease. Am J Clin Nutr. 2006 Jun;83(6 Suppl):1477S-1482S.
3. Meyer BJ, Lane AE, Mann NJ. Comparison of seal oil to tuna oil on plasma lipid levels and blood pressure in hypertriglyceridaemic subjects. Lipids. 2009 Sep;44(9):827-35.
4. Grynberg A. Hypertension prevention: from nutrients to (fortified) foods to dietary patterns. Focus on fatty acids. J Hum Hypertens. 2005 Dec;19 Suppl 3:S25-33.

Triglycerides and HDL

1. Saito Y, Yokoyama M, Origasa H, Matsuzaki M, Matsuzawa Y, Ishikawa Y, Oikawa S, Sasaki J, Hishida H, Itakura H, Kita T, Kitabatake A, Nakaya N, Sakata T, Shimada K, Shirato K; JELIS Investigators, Japan. Effects of EPA on coronary artery disease in hypercholesterolemic patients with multiple risk factors: sub-analysis of primary prevention cases from the Japan EPA Lipid Intervention Study (JELIS). Atherosclerosis. 2008 Sep;200(1):135-40. Epub 2008 Jun 19.
2. Zuliani G, Galvani M, Leitersdorf E, Volpato S, Cavalieri M, Fellin R. The role of polyunsaturated fatty acids (PUFA) in the treatment of dyslipidemias. Curr Pharm Des. 2009;15(36):4087-93.
3. Pishva H, Mahboob SA, Mehdipour P, Eshraghian MR, Mohammadi-Asl J, Hosseini S, Karimi F. Fatty acid-binding protein-2 genotype influences lipid and lipoprotein response to eicosapentaenoic acid supplementation in hypertriglyceridemic subjects. Nutrition. 2010 Jan 15.
4. McKenney JM, Sica D. Role of prescription omega-3 fatty acids in the treatment of hypertriglyceridemia. Pharmacotherapy. 2007 May;27(5):715-28.
5. Skulas-Ray AC, West SG, Davidson MH, Kris-Etherton PM. Omega-3 fatty acid concentrates in the treatment of moderate hypertriglyceridemia. Expert Opin Pharmacother. 2008 May;9(7):1237-48.
6. De Luis DA, Conde R, Aller R, Izaola O, González Sagrado M, Perez Castrillón JL, Dueñas A, Romero E. Effect of omega-3 fatty acids on cardiovascular risk factors in patients with type 2 diabetes mellitus and hypertriglyceridemia: an open study. Eur Rev Med Pharmacol Sci. 2009 Jan-Feb;13(1):51-5.
7. von Schacky C. A review of omega-3 ethyl esters for cardiovascular prevention and treatment of increased blood triglyceride levels. Vasc Health Risk Manag. 2006;2(3):251-62.

LiqFillCaps^TM are an innovative technological concept that provides an efficient solution to the many challenges the pharmaceutical and nutraceutical industries face, in particular those due to the low solubility of active ingredients and bioactive agents, thereby helping to achieve an increase in both oral bioavailability and absorption.